These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Potent and selective antitumor activity of a T cell-engaging bispecific antibody targeting a membrane-proximal epitope of ROR1. Qi J; Li X; Peng H; Cook EM; Dadashian EL; Wiestner A; Park H; Rader C Proc Natl Acad Sci U S A; 2018 Jun; 115(24):E5467-E5476. PubMed ID: 29844189 [TBL] [Abstract][Full Text] [Related]
7. A new class of bispecific antibodies to redirect T cells for cancer immunotherapy. Rossi DL; Rossi EA; Cardillo TM; Goldenberg DM; Chang CH MAbs; 2014; 6(2):381-91. PubMed ID: 24492297 [TBL] [Abstract][Full Text] [Related]
8. Claudin18.2-Specific Chimeric Antigen Receptor Engineered T Cells for the Treatment of Gastric Cancer. Jiang H; Shi Z; Wang P; Wang C; Yang L; Du G; Zhang H; Shi B; Jia J; Li Q; Wang H; Li Z J Natl Cancer Inst; 2019 Apr; 111(4):409-418. PubMed ID: 30203099 [TBL] [Abstract][Full Text] [Related]
9. [Bispecific antibodies: An old story with a bright future… with CAR-T cells!]. Riffard C; Teillaud JL Bull Cancer; 2021 Oct; 108(10S):S168-S180. PubMed ID: 34920800 [TBL] [Abstract][Full Text] [Related]
10. Human macrophages engineered to secrete a bispecific T cell engager support antigen-dependent T cell responses to glioblastoma. Gardell JL; Matsumoto LR; Chinn H; DeGolier KR; Kreuser SA; Prieskorn B; Balcaitis S; Davis A; Ellenbogen RG; Crane CA J Immunother Cancer; 2020 Oct; 8(2):. PubMed ID: 33122397 [TBL] [Abstract][Full Text] [Related]
11. Activating Macrophage-Mediated Cancer Immunotherapy by Genetically Edited Nanoparticles. Rao L; Zhao SK; Wen C; Tian R; Lin L; Cai B; Sun Y; Kang F; Yang Z; He L; Mu J; Meng QF; Yao G; Xie N; Chen X Adv Mater; 2020 Nov; 32(47):e2004853. PubMed ID: 33089578 [TBL] [Abstract][Full Text] [Related]
12. Trispecific natural killer cell nanoengagers for targeted chemoimmunotherapy. Au KM; Park SI; Wang AZ Sci Adv; 2020 Jul; 6(27):eaba8564. PubMed ID: 32923587 [TBL] [Abstract][Full Text] [Related]
13. Differential Effects of Depleting versus Programming Tumor-Associated Macrophages on Engineered T Cells in Pancreatic Ductal Adenocarcinoma. Stromnes IM; Burrack AL; Hulbert A; Bonson P; Black C; Brockenbrough JS; Raynor JF; Spartz EJ; Pierce RH; Greenberg PD; Hingorani SR Cancer Immunol Res; 2019 Jun; 7(6):977-989. PubMed ID: 31028033 [TBL] [Abstract][Full Text] [Related]
14. Highly effective recombinant format of a humanized IgG-like bispecific antibody for cancer immunotherapy with retargeting of lymphocytes to tumor cells. Asano R; Watanabe Y; Kawaguchi H; Fukazawa H; Nakanishi T; Umetsu M; Hayashi H; Katayose Y; Unno M; Kudo T; Kumagai I J Biol Chem; 2007 Sep; 282(38):27659-65. PubMed ID: 17644522 [TBL] [Abstract][Full Text] [Related]
15. Design, selection and optimization of an anti-TRAIL-R2/anti-CD3 bispecific antibody able to educate T cells to recognize and destroy cancer cells. Satta A; Mezzanzanica D; Caroli F; Frigerio B; Di Nicola M; Kontermann RE; Iacovelli F; Desideri A; Anichini A; Canevari S; Gianni AM; Figini M MAbs; 2018 Oct; 10(7):1084-1097. PubMed ID: 29993310 [TBL] [Abstract][Full Text] [Related]
16. Targeting CLDN18.2 by CD3 Bispecific and ADC Modalities for the Treatments of Gastric and Pancreatic Cancer. Zhu G; Foletti D; Liu X; Ding S; Melton Witt J; Hasa-Moreno A; Rickert M; Holz C; Aschenbrenner L; Yang AH; Kraynov E; Evering W; Obert L; Lee C; Sai T; Mistry T; Lindquist KC; Van Blarcom T; Strop P; Chaparro-Riggers J; Liu SH Sci Rep; 2019 Jun; 9(1):8420. PubMed ID: 31182754 [TBL] [Abstract][Full Text] [Related]
17. CSF-1R-Dependent Lethal Hepatotoxicity When Agonistic CD40 Antibody Is Given before but Not after Chemotherapy. Byrne KT; Leisenring NH; Bajor DL; Vonderheide RH J Immunol; 2016 Jul; 197(1):179-87. PubMed ID: 27217585 [TBL] [Abstract][Full Text] [Related]
18. An engineered anti-CA19-9 cys-diabody for positron emission tomography imaging of pancreatic cancer and targeting of polymerized liposomal nanoparticles. Girgis MD; Federman N; Rochefort MM; McCabe KE; Wu AM; Nagy JO; Denny C; Tomlinson JS J Surg Res; 2013 Nov; 185(1):45-55. PubMed ID: 23827791 [TBL] [Abstract][Full Text] [Related]
19. Dendritic cells engineered to secrete anti-DcR3 antibody augment cytotoxic T lymphocyte response against pancreatic cancer Chen J; Guo XZ; Li HY; Zhao JJ; Xu WD World J Gastroenterol; 2017 Feb; 23(5):817-829. PubMed ID: 28223726 [TBL] [Abstract][Full Text] [Related]
20. A Rationally Designed Fully Human EGFRvIII:CD3-Targeted Bispecific Antibody Redirects Human T Cells to Treat Patient-derived Intracerebral Malignant Glioma. Gedeon PC; Schaller TH; Chitneni SK; Choi BD; Kuan CT; Suryadevara CM; Snyder DJ; Schmittling RJ; Szafranski SE; Cui X; Healy PN; Herndon JE; McLendon RE; Keir ST; Archer GE; Reap EA; Sanchez-Perez L; Bigner DD; Sampson JH Clin Cancer Res; 2018 Aug; 24(15):3611-3631. PubMed ID: 29703821 [No Abstract] [Full Text] [Related] [Next] [New Search]